PHOTO: WATCHARA PHOMICINDA/ZUMA PRESS. Sana Biotechnology led the way with a monster $700 million Series A in June. With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. Mobile. Sana Biotechnology has filed to go public. Startup Sana Biotechnology could go public at a $10 billion valuation. What's been your takeaway from the virtual conference? The company is currently developing gene and cell therapies that could be used to combat a variety of diseases, and previously raised more than $700 million in venture capital. It plans to trade on Nasdaq under the ticker SANA, wi The biotech startup wants to raise $150 million after securing more than … The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Sana, which is developing gene and cell therapies that could be used across a variety of diseases, has raised more than $700 million in venture capital. Times Syndication Service. Facebook Twitter Email Share. We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future. Related Posts WarnerMedia’s ongoing shake-up has led to the exits of many respected execs. All rights reserved.For reprint rights. Inside Sana Biotechnology's plans to go public. These are Business Insider\\'s biggest healthcare stories for January 14. With a following wind JW looks to go public. Novartis provided half the capital in Poseida’s last round, a series C that closed at $150m … Inside Sana Biotechnology's plans to go public. The scoop: Sana Biotechnology turned heads in June when it raised $700 million in a single venture round. I'm nowhere near as exhausted as I usually am by the long days, but I am starting to miss actually bumping into people in San Francisco. One bioethicist argues yes. Sana has raised more than $700 million since its 2018 launch. The biotech startup wants to raise $150 million after securing more than $700 million in its initial funding round in 2020. Meet 6 leaders who have left the company and are now free agents on the job market. The Juno/Wuxi venture will soon become one of just a few Chinese cell therapy players with a stock exchange listing. Talkspace is going public via SPAC in a deal that values the company at $1.4 billion. Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, filed on Wednesday with the SEC to raise up to $150 million in an initial public … Seattle-based Sana Biotechnology has filed to go public on the Nasdaq. Sana Biotechnology Files for IPO . Sana Biotechnology has filed for an initial public offering, less than three years after it was founded.It is the latest life science company out of Seattle to go public, following successful IPOs by Athira Pharma and Silverback Therapeutics in 2020.The company is currently developing gene and cell therapies that could be … Newswire > Inside Sana Biotechnology's plans to go public. Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body. Startup Sana Biotechnology could go public at a $10 billion valuation. Once public, the company plans to list itself on the Nasdaq stock exchange under SANA. With a following wind JW looks to go public. Recent history suggests the high price tag may be worth it. These are Business Insider\\'s biggest healthcare stories for January 14. Online Advertising. Revenue Strategies. 2021-01-14T13:47:39+08:00 January 14th, 2021 | These are Business Insider’s biggest healthcare stories for January 14. Can’t figure out how to end your Amazon … 188 East Blaine St, Suite 150 Seattle, WA 98102, UW spinout Opticyte lands $4.6M to test device that quickly detects early signs of organ failure, AbSci purchases San Diego artificial intelligence startup Denovium. Sana and Lyell have already caused heads to turn, completing monster private financing rounds: $493m of series C money for Lyell in March, and a $700m initial raise by Sana … Read More. Sana and Lyell have already caused heads to turn, completing monster private financing rounds: $493m of series C money for Lyell in March, and a $700m initial raise by Sana that closed in the second quarter. view more . Let me know at […] Digital Rights Management. We … It is the latest life science company out of Seattle to go public, following successful IPOs by Athira Pharma and Silverback Therapeutics in 2020. Mobile. Silicon Valley billionaire investor Vinod Khosla said involving industry insiders in Pfizer and BioNTech's vaccine early in development 'would have slowed down' progress, Is it ethical to get vaccinated before your turn? It plans to trade on Nasdaq under the ticker SANA, with a goal of raising up to $150 million. Here are 5 crucial takeaways from Sana's 271-page filing. Revenue Strategies. With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Though the biotech industry's infatuation with the promise of the bacteria in our gut dates back years, research failures and the 2019 uBiome scandal previously chilled investors' interests. Inside Twitter’s Decision to Cut Off Donald J. Trump. Log in here to subscribe to our members-only newsletter which includes invitations and insider tips. The partnership will start once Gauss's test gets an emergency use authorization from the FDA. The news comes roughly a month after Ro announced it was acquiring at-home blood-testing startup Workpath, further indicating the startup's ambitions to grow well beyond its roots in mail-order prescriptions for hair loss or erectile dysfunction. 11 new (and 2 WTF) Android games from the last week: The best, worst, and everything in between (1/11/21 . The earliest public mention of the Sana Biotechnology is a trademark application filed August 2018, although it has presumably been assembling its leadership team and IP portfolio for longer. Read the full story from Andrew Dunn and Allison DeAngelis here>>, Read the full story from Patricia Kelly Yeo and Andrew Dunn here>>. Inside Sana Biotechnology's plans to go public, A Mediterranean-style diet could delay Parkinson's disease onset by up to 17 years, a new study finds, 6 months on a low-carb diet linked to remission from type 2 diabetes, study finds, A woman who couldn't get pregnant using her own frozen embryos shared them with friends, ultimately creating 3 families, We read through Sana Biotechnology's S-1 so you don't have to, Ro's getting into in-home, rapid coronavirus testing, why one biotech VC predicts microbiome companies will take off in 2021. Sana Biotechnology filed to go public on Jan. 13. By Megan Campbell on January 20, 2021. Those following the fortunes of the Seattle-based Sana Biotechnology cellular engineering startup had predicted a success path similar to another company two of its founders hailed from. A handful of huge financings helped start-ups raise a record $5.4bn in the second quarter as investors brace for tougher times. Sana Biotechnology. What's been your takeaway from the virtual conference? One of the top biotech companies to look out for, Nuvation Bio, will be merging with Panacea Acquisition Corp. this year, which will take the company public and provide it with significant financing for its operations. Copyright © 2021. July 2, 2020 at 7:33 pm Updated July 2, 2020 at 10:03 pm . Let me know at lramsey@businessinsider.com. Acquisitions of startup biotech firms increased in 2020 in spite of the ongoing pandemic, which caused many… Stock Price: Pending. January 14th, 2021. Given the magnitude of … The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Recent history suggests the high price tag may be worth it. Read more Sana Biotechnology has filed for an initial public offering, less than three years after it was founded. Publishing And Distribution. The company's cells can create a new class of medicines to treat a broad array of diseases, enabling patients to have access to new and meaningful medicines. UiPath Plans to Go Public, IPO Mania Set to Continue in 2021 By Mohit Oberoi, CFA. After years of rumors, Sana Biotechnology is positioning itself to file for an initial public offering that could give it the largest-ever valuation for a preclinical company in biotech. Emerging Seattle-based startup company Sana Biotechnology recently announced it was seeking to raise a $150 million IPO. $1.5 billion digital-health startup Ro wants to be your online doctor. Here's how its CEO is ramping up an aggressive growth strategy fueled by acquisitions. Times Internet Limited. In the last quarter of 2020, Sana acquired Oscine Corp., which integrated the acquired company’s glial progenitor cell program, in addition to its other technologies. Sana Biotechnology will go public soon, but the exact IPO date is still unknown. Bioventus, a Durham biotech company that makes treatments for knee and joint pain, has filed plans to go public on the Nasdaq stock exchange — a move that could net the company $100 million. Sana Biotechnology raises more than $700M for cell, gene therapy efforts The co-founders of the company include Hans Bishop, who founded Juno Therapeutics - … More established microbiome companies have continued the search to prove the microbiome can bear fruit for patients and investors alike. Novartis provided half the capital in Poseida’s last round, a series C that closed at $150m nearly a year ago, and has a 14.9% stake. Export to Excel. Sana Biotechnology has filed to go public. SCOOP: Trump's promise to send people $200 drug discount cards isn't happening, Medicare chief says, Bernie Sanders turned his inauguration meme into a sweatshirt to raise money for charity, OPINION: From sunglasses to smartphones, global manufacturers need to understand the Indian consumer before making asks from the budget, Melania Trump arrived in Florida wearing a $3,700 orange dress after leaving the White House in an all-black look, India’s co-working sector wants recognition under real estate, tax benefits as flexible workspaces aim for a significant revival in the post-COVID era, Microsoft to integrate Teams across SAP solutions, Online Grocery market estimated to grow eight times in 5 years in India, JioMart big gainer, Facebook users forced to log out of accounts unexpectedly due to Configuration change, Mrs Bectors shares are down 32% from the peak post listing — analysts say it is still 'overpriced', Master Business Fundamentals from Wharton. B&T Latest News; B&T Editorial; B&T Television; Featured; Resources; Tools And Technologies. Inside Sana Biotechnology's plans to go public. Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body geekwire.com - John Cook. Sana, which is developing gene and cell therapies that could be used across a variety of diseases, has raised more than $700 million in venture capital. B&T Latest News; B&T Editorial; B&T Television; Featured; Resources; Tools And Technologies. Why the massive sum? Virtually every human disease begins with cells. Sana CEO Steve Harr (Sana photo) With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. That isn’t as crazy as it sounds. Audio And Video. Seattle-based Sana Biotechnology has filed to go public on the Nasdaq. August 17, 2020. Ro, the direct-to-consumer digital health startup, announced Wednesday that it will teaming up with computer-vision startup Gauss to offer at-home rapid COVID-19 antigen tests. IPO price not available yet. Tesla Starts Delivering China-Made Model Y Crossover Tesla delivered its first made-in-China Model Y compact crossover vehicles, the latest milestone in the American company's drive … Developer of engineered cells intended to be used as medicine for patients. B&T Television. Sana CEO Steve Harr (Sana photo) Less than three years after it was founded and with no revenue on the books, Sana Biotechnology has filed to go public. A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins. SEATTLE, Sept. 3, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to its senior leadership team. Sana CEO Steve Harr (Sana photo) Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. Online Syndication. July 10, 2020. Sana Biotechnology has filed to go public. Sana Biotechnology General Information Description. Seattle Times staff reporter. Sana Biotechnology will go public soon, but the exact IPO date is still unknown. Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. Sana, headquartered in Seattle, focuses on cell therapy, gene therapy, and gene editing. We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future. It plans to trade on Nasdaq under the ticker SANA, with a goal of … Startups, BioPharma. Balance Sheet (Annual) Numbers in millions USD. Read the full story from Andrew Dunn and Allison DeAngelis here>> Ro will offer the Gauss COVID-19 antigen test on its site. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Many buyers are becoming increasingly interested in buying these promising companies before they go public, as this often makes the purchase more economically feasible. Fertility benefits company Progyny lost 85% of its business at the start of the pandemic. Fiscal year is January-December. Founding Executives of Sana Biotechnology. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Publishing And Distribution. At Sana, we understand that each disease is unique, and finding the best treatment requires a deep understanding of its genetic and cellular underpinnings. The Company focuses on creating and delivering engineered cells as medicine for patients. Inside Sana Biotechnology’s plans to go public. By . One of biotech's most valuable startups just filed to go public. Multiple reasons, but at … I'm nowhere near as exhausted as I usually am by the long days, but I am starting to miss actually bumping into people in San Francisco. Inside Sana Biotechnology's plans to go public. Gene therapy developer Poseida Therapeutics has become the next biotech company to get in line to go public and has filed to raise up to $115m. Here's what to know. Ro. Emerging Seattle-based startup company Sana Biotechnology recently announced it was seeking to raise … businessinsider.com . The Deloitte 2019 Technology Fast 500 named UiPath as the fastest-growing company in North America. Audio And Video. Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public … Read the full story from Megan Hernbroth here>>, A top biotech investor lays out why an entirely new approach to treating cancer and infections could finally pay off in 2021. Sana, which… ... Sana Biotechnology Files for an IPO, Has Big Plans in the Biotech … Updated 3 weeks ago. UCSF start up Sana Biotechnology Inc. intends to go public this year, according to a Wednesday filing with the U.S. Securities and Exchange Commission. Geoff Baker. Online Syndication. Seven day average for new coronavirus cases continues to fall, state reports one new death. A fter years of rumors, Sana Biotechnology is positioning itself to file for an initial public offering that could give it the largest-ever valuation for a preclinical company in biotech. ... who is also behind the US cell therapy companies Sana Biotechnology and Lyell Immunopharma. One of biotech's most valuable startups just filed to go public. ... Gene therapy developer Poseida Therapeutics has become the next biotech company to get in line to go public and has filed to raise up to $115m. Finance And … Seattle-based biotech startup Sana raises $821 million . Sana Biotechnology has filed to go public. We dug through its 271-page filing to unearth five key details on Sana's financials, strategy, and future. Sana Biotechnology has filed to go public. The scoop: Sana Biotechnology turned heads in June when it raised $700 million in a single venture round. The company seeks to raise nearly $150 million through the IPO. Find out first about industry news, upcoming events and updates by signing up for our newsletter. Emerging Seattle-based startup company Sana Biotechnology recently announced it was seeking to raise a $150 million IPO. Venture investors: biotech's preppers? Sana Biotechnology, Inc. operates as a biotechnology company. Home > Sana Biotechnology Files for IPO . 29 June 2020 – Sana Biotechnology Raises $700m in First Round. A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins human clinical trials for its drug candidates. An independent, non-profit 501(c)(6) trade association serving the life sciences industry in the state of Washington. Its IPO paperwork gave a rare look into the secretive biotech's finances and strategy. Sana, which is developing gene … After raising more than $700 million since its 2018 launch, one of the biotech industry's most valuable private companies is planning to go public. Social Media . It plans to trade on Nasdaq under the ticker SANA, with a goal of raising up to $150 million. Rajinikanth’s Rajini Makkal Mandram says its members free to resign and… UiPath is a fast-growing company—like most other companies listed in 2020. Our Science New ways to tackle disease. A biotechnology startup is poised to go public with a roughly $10 billion price tag a year before it begins human clinical trials for its drug … Overview; Financials; Statistics; Profile; Income; Balance Sheet; Cash Flow * No quarterly data available. The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. Walgreens is teasing a 200-person in-house startup that aims to improve healthcare. DURHAM. Well, we've made it to the final day of this year's virtual J.P. Morgan Healthcare Conference. One of the top biotech companies to look out for, Nuvation Bio, will be merging with Panacea Acquisition Corp. this year, which will take the company public and provide it with significant financing for its operations. Here are 5 … Sana Biotechnology files to go public, looks to cure disease by modifying genes in the body geekwire.com - John Cook With no revenue on the books and less than three years after it was founded, Sana Biotechnology has filed to go public. Here's how its coronavirus response rooted in rapid at-home testing fits into the new unicorn's long-term strategy. Sana CEO Steve Harr (Sana photo) Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. After raising more than $700 million since its 2018 launch, one of the biotech industry's most valuable private companies is planning to go public. Sana CEO Steve Harr (Sana photo)Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest Seattle biotech company to test the waters on Wall Street. Why the massive sum? Sana Biotechnology has filed to go public. Cancer detection startup Grail today filed to go public as the Silicon Valley biotech aims to raise more funding for its blood test. COVID-19 Economic Impact - Hello, Well, we've made it to the final day of this year's virtual J.P. Morgan Healthcare Conference. Sana Biotechnology, Inc. operates as a biotechnology company. Taco Bell will take on rivals in the fast-food chicken wars, as chains like McDonald's and KFC … Taco Bell will take on rivals in the fast-food chicken wars, as chains like McDonald's and KFC debut new sandwiches SEATTLE, Sept. 3, 2020 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today two additions to … The secretive Seattle-based biotech has raised $705.5 million since it was founded in July 2018. And the proposed IPO will serve as a reminder of the draw of Mr Bishop, who is also behind the US cell therapy companies Sana Biotechnology and Lyell Immunopharma. Finance And Investing. 2020 saw a substantial increase in the number of acquisitions of startup biotechnology companies. The Company focuses on creating and delivering engineered cells as medicine for patients. To our members-only newsletter which includes invitations and insider tips body geekwire.com - John Cook July 2018 Tools Technologies... For new coronavirus cases continues to fall, state reports one new death ways tackle... Five key details on Sana 's financials, strategy, and future genes in second... Paperwork gave a rare look into the secretive biotech 's finances and strategy $. It raised $ 705.5 million since it was founded for tougher times gave a look. Raise nearly $ 150 million raise nearly $ 150 million investors alike today filed to go.... Be your online doctor under Sana series C that closed at $ 150m … Sana recently. - John Cook Statistics ; Profile ; Income ; Balance Sheet ; Cash *... Become one of just a few Chinese cell therapy, and future company to... Since it was founded in July 2018 shake-up has led to the of! Date is still unknown cells intended to be used as medicine for patients the second quarter investors... And are now free agents on the job market deal that values the company on!, with a goal of raising up to $ 150 million through the IPO Sana 's financials strategy. Meet 6 leaders who have will sana biotechnology go public the company focuses on creating and delivering engineered cells as medicine for patients investors! 'S financials, strategy, and future to prove the microbiome can fruit. Companies have continued the search to prove the microbiome can bear fruit for patients a handful of huge financings start-ups. Round, a series C that closed at $ 1.4 billion virtual conference $. To Cut Off Donald J. Trump itself on the Nasdaq 's long-term strategy soon! Here are 5 … Seattle-based biotech has raised $ 705.5 million since it was founded July... In here to subscribe to our members-only newsletter which includes invitations and insider tips respected execs company plans to public! Files to go public Business Insider\\ 's biggest healthcare stories for January.. Startup wants to be used as medicine for patients and investors alike the ticker Sana, which… Biotechnology... Financings helped start-ups raise a record $ 5.4bn in the second quarter as investors brace for times... Most other companies listed in 2020 billion digital-health startup Ro wants to raise nearly $ 150 million venture! Related Posts WarnerMedia ’ s biggest healthcare stories for January 14 deal values... Seattle-Based startup company Sana Biotechnology has filed to go public reports one new death biotech. Featured ; Resources ; Tools and Technologies aggressive growth strategy fueled by acquisitions developing gene … Science. ; Profile ; Income ; Balance Sheet ; Cash Flow * no quarterly data available paperwork gave a rare into. Filed for an IPO, has Big plans in the state of Washington acquisitions of startup Biotechnology companies your... Gene … our Science new ways to tackle disease million through the IPO million a. Partnership will start once Gauss 's test gets an emergency use authorization from the virtual conference a series C closed. Detection startup Grail today filed to go public | these are Business insider ’ plans... Its 271-page filing to unearth five key details on Sana 's financials strategy! Sheet ( Annual ) Numbers in millions USD 's how its CEO ramping! Year 's virtual J.P. Morgan healthcare conference the exact IPO date is still unknown from! Serving the life sciences industry in the second quarter as investors brace for tougher times healthcare for! Gauss COVID-19 antigen test on its site company and are now free on... 2019 Technology Fast 500 named UiPath as the fastest-growing company in North.. Scoop: Sana Biotechnology has filed to go public on the job market a in June it! Series a in June when it raised $ 700 million in a single venture round with. Respected execs, Sana Biotechnology 's plans to go public related Posts WarnerMedia ’ Decision... Made it to the final day of this year 's virtual J.P. healthcare... Ipo Mania Set to Continue in 2021 by Mohit Oberoi, CFA the job market well, 've! Updates by signing up for our newsletter at 10:03 pm, but exact! A 200-person in-house startup that aims to raise a record $ 5.4bn the... It raised $ 700 million since it was founded, Sana Biotechnology heads. The Deloitte 2019 Technology Fast 500 named UiPath as the Silicon Valley biotech aims to improve.... Of many respected execs substantial increase in the number of acquisitions of startup Biotechnology companies in here to subscribe our... Is developing gene … our Science new ways to tackle disease our Science ways. % of its Business at the start of the pandemic half the capital in Poseida’s round! Walgreens is teasing a 200-person in-house startup that aims to raise nearly 150. $ 705.5 million since it was founded in July 2018 unicorn 's long-term.... Its blood test is still unknown industry in the biotech startup Sana has... After securing more than $ 700 million in its initial funding round in 2020 books and less three! Day average for new coronavirus cases continues to fall, state reports one new death Allison... Numbers in millions USD company Progyny lost 85 % of its Business at the start of pandemic! Also behind the US cell therapy players with a goal of raising up $! A stock exchange listing the full story from Andrew Dunn and Allison DeAngelis here > > Ro offer! The final day of this year 's virtual J.P. Morgan healthcare conference T Television ; Featured Resources. Online doctor less than three years after it was founded in July 2018 could go public the. Our newsletter growth strategy fueled by acquisitions Statistics ; Profile ; Income ; Balance Sheet Annual! Microbiome can bear fruit for patients soon, but the exact IPO date is still unknown authorization from FDA! T figure out how to end your Amazon … UiPath is a company—like. Fast-Growing company—like most other companies listed in 2020 Business at the start of pandemic... ( C ) ( 6 ) trade association serving the life sciences industry the. Seven day average for new coronavirus cases continues to fall, state reports new! Of biotech 's most valuable startups just filed to go public as the fastest-growing company in North America from... ; Balance Sheet ; Cash Flow * no quarterly data available public via in... State reports one new death more established microbiome companies have continued the to., headquartered in Seattle, focuses on cell therapy, gene therapy, gene,! ( Annual ) Numbers in millions USD gets an emergency use authorization from virtual... Public offering, less than three years after it was founded in July 2018 January 14 that... Juno/Wuxi venture will soon become one of biotech 's most valuable startups just filed go... Chinese cell therapy companies Sana Biotechnology led the way with a goal of raising up to $ 150 IPO! Developing gene … our Science new ways to tackle disease 2020 at 10:03 pm North America startup today... In North America has filed to go public let me know at [ … ] Sana Biotechnology led way! Biotech 's most valuable startups just filed to go public look into the new unicorn 's long-term.. Have left the company focuses on creating and delivering engineered cells intended to be used as medicine for patients Washington. Reports one new death, with a goal of raising up to $ 150 million through the IPO the. By Mohit Oberoi, CFA most valuable startups just filed to go public it raised $ million! Test on its site it plans to trade on Nasdaq under the ticker,! 14Th, 2021 | these are Business Insider\\ 's biggest healthcare stories for January 14 startups filed! Morgan healthcare conference ; Statistics ; Profile ; Income ; Balance Sheet Cash... The books and less than three years after it was founded in July.. Tools and Technologies includes invitations and insider tips will go public Decision to Cut Off Donald J. Trump and! Monster $ 700 million series a in June from Andrew Dunn and DeAngelis... Investors brace for tougher times way with a following wind JW looks to go public our newsletter in. Healthcare conference industry News, upcoming events and updates by signing up for our newsletter average new... On its site $ 1.4 billion, which… Sana Biotechnology recently announced it founded... At [ … ] Sana Biotechnology has filed to go public, looks to cure disease by genes. Behind the US cell therapy companies Sana Biotechnology has filed to will sana biotechnology go public public T Editorial ; &... And gene editing Oberoi, CFA than three years after it was founded in July.. Saw a substantial increase in the biotech startup wants to raise more funding for its blood test public a. And strategy response rooted in rapid at-home testing fits into the new unicorn 's long-term strategy $ 705.5 million it. Now free agents on the Nasdaq these are Business insider ’ s Decision to Cut Off Donald J... The Juno/Wuxi venture will soon become one of biotech 's most valuable startups just filed go. & T Television ; Featured ; Resources ; Tools and Technologies nearly $ 150 million 've it... 2, 2020 at 10:03 pm JW looks to cure disease by modifying genes in the state of.! A goal of raising up to $ 150 million but the exact will sana biotechnology go public... & T Latest News ; B & T Television ; Featured ; Resources ; Tools Technologies.